Benzinga | Jul 15, 2021 10:37AM EDT

Canaccord Genuity Upgrades Acutus Medical to Buy, Raises Price Target to $18

Canaccord Genuity analyst William Plovanic upgrades Acutus Medical (NASDAQ:AFIB) from Hold to Buy and raises the price target from $11 to $18.